Phase 2
N=239
The Safety and Efficacy of OPC-64005 in the Treatment of Adult Attention-deficit/Hyperactivity Disorder
Adult Attention Deficit Hyperactivity Disorder
Bottom Line
View on ClinicalTrials.gov: NCT03324581 ↗Enrolled (actual)
239
Serious AEs
0.4%
Results posted
Oct 2021
Primary outcome: Primary: Change From Baseline in Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) 18-item ADHD Symptoms Total Score at Day 56 — 40.71; 41.59; 40.51; -19.4 score on a scale — p==0.7554
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- OPC-64005 (Drug); Atomoxetine (Drug); Placebo (Drug)
- Age
- Adult · 18+ yrs
- Sex
- All
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
- Primary completion
- Oct 2018
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Change From Baseline in Conners' Adult ADHD Rating Scales-Observer: Screening Version (CAARS-O:SV) 18-item ADHD Symptoms Total Score at Day 56 |
40.71; 41.59; 40.51; -19.4; -20.2; -10.3 | =0.7554 |
Summary
A trial to assess the safety and efficacy of OPC-64005 in the treatment of adult attention-deficit/hyperactivity disorder.
Eligibility Criteria
Inclusion Criteria (Screening):
- Male and female participants 18 to 55 years of age, inclusive, at the time of informed consent.
- Participants with a primary Diagnostic and Statistical Manual of Mental Disorders, 5th edition (DSM-5) diagnosis of ADHD (including predominantly inattentive presentation, hyperactive presentation, and combined presentations) as confirmed by the Adult ADHD Clinical Diagnostic Scale (ACDS) v 1.2.
- Participants willing to discontinue all prohibited psychotropic medication starting from the time of signing the informed consent and up to the 30 (+ 2)-day follow-up period.
Exclusion Criteria
- Participants with a history of inadequate response or suboptimal tolerability to atomoxetine.
- Participants who report allergies (lifetime treatment history) to stimulant or nonstimulant ADHD medications.
- Participants with other DSM-5 disorders including psychosis (current or lifetime), bipolar disorder (current or lifetime), current major depressive disorder, or current panic disorder; or another psychiatric diagnosis that the investigator believes is primary or that will confound efficacy or safety assessments of the trail or interfere with participation in the trial otherwise.
- Participants with a clinically significant current DSM-5 diagnosis of borderline, antisocial, paranoid, schizoid, schizotypal, histrionic, narcissistic, avoidant, obsessive compulsive, or dependent personality disorders.
- Participants who currently have clinically significant dermatological, neurological, hepatic, renal, metabolic, hematological, immunological, cardiovascular, pulmonary, or gastrointestinal disorders such as any history of myocardial infarction, congestive heart failure, HIV (human immunodeficiency virus) seropositive status/acquired immunodeficiency syndrome, or active or chronic hepatitis B or C.
- Participants with a history of obstructive sleep apnea.
Data sourced from ClinicalTrials.gov (NCT03324581). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.